Does bipolar II deserve a new name π·οΈ? In our new Insight in European Neuropsychopharmacology, we argue yes.
BD-II is distinct in phenomenology π§ , illness course π, genetics π§¬, and treatment response π. Renaming could shift the paradigm π & improve care β¨
π
authors.elsevier.com/c/1n1Q4,L21E...